18F-labelling of a potent nonpeptide CCR1 antagonist: Synthesis of 1-(5-chloro-2-{2-[(2r)-4-(4-[18F]fluorobenzyl)-2-methylpiperazin- 1-yl]-2-oxoethoxy}phenyl)urea in an automated module

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 49, Issue 3, 2006, Pages 253-262

  Mading P ^a   Fuchtner F ^a   Johannsen, B ^a   Steinbach, J ^b   Hilger, C S ^c   Friebe, M ^c   Halks Miller, M ^d   Horuk, R ^d   Mohan, R ^e  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b Institut fur Interdisziplinare Isotopenforschung   (Germany)

^c BAYER PHARMA AG   (Germany)

^d BAYER AG   (Germany)

^e EXELIXIS INC   (United States)

Author keywords

4 18F fluorobenzaldehyde; Alzheimer's disease; Automated module synthesis; CCR1 antagonist; Positron emission tomography; Reductive amination

Indexed keywords

AMINES; FILTRATION; FLUORINE COMPOUNDS; METABOLISM; NEURODEGENERATIVE DISEASES; PHASE SEPARATION; POSITRON EMISSION TOMOGRAPHY; SODIUM COMPOUNDS;

4-[18F] FLUOROBENZALDEHYDE; ALZHEIMERS DISEASE; AUTOMATED MODULE SYNTHESIS; CCR1 ANTAGONIST; LABELINGS; NONPEPTIDE; ONE-POT PROCEDURES; PIPERAZINE DERIVATIVES; REDUCTIVE AMINATION; SODIUM CYANOBOROHYDRIDE;

UREA;

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYLPIPERAZIN 1 YL] 2 OXOETHOXY]PHENYL]UREA; 4 FLUOROBENZALDEHYDE; BENZALDEHYDE DERIVATIVE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CYANOBOROHYDRIDE SODIUM; FLUORODEOXYGLUCOSE F 18; PIPERAZINE DERIVATIVE; SODIUM BOROHYDRIDE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ALZHEIMER DISEASE; AMINATION; ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RADIOCHEMISTRY; SOLID PHASE EXTRACTION;

EID: 33645766765     PISSN: 03624803     EISSN: 10991344     Source Type: Journal    
DOI: 10.1002/jlcr.1023     Document Type: Article

References (10)

1. Liang M, Mallari C, Rosser M, Ng HP, May K, Monahan S, Bauman JG, Islam I, Ghannam A, Buckman B, Shaw K, Wei G-P, Xu W, Zhao Z, Ho E, Shen J, Oanh H, Subramanyam B, Vergona R, Taub D, Dunning L, Harvey S, Snider RM, Hesselgesser J, Morrissey MM, Perez HD, Horuk R. J Biol Chem 2000; 275: 19000-19008.
2. Halks-Miller M, Schroeder ML, Haroutunian VM, Moenning U, Rossi M, Achim C, Purohit D, Mahmoudi M, Horuk R. Ann Neurol 2003; 54: 638-646.
3. Dinter H, Halks-Miller M, Hesselgesser J, Hilger CS, Horuk R, Johannsen B, Mäding P, Mohan R, Steinbach J. PCT, WO 02/36581, 1 November, 2001; US 6,676,926 B2, 13 January 2004.
4. Wilson AA, Dannals RF, Ravert HT, Wagner Jr HN. J Label Compd Radiopharm 1990; 28: 1189-1199.
5. Damhaut P, Cantineau R, Lemaire C, Plenevaux A, Christiaens L, Guillaume M. Appl Radiat Isot 1992; 43: 1265-1274.
6. Haka MS, Kilbourn MR, Watkins GL, Toorongian SA. J Label Compd Radiopharm 1989; 27: 823-833.
7. Iwata R, Pascali C, Bogni A, Horvath G, Kovács Z, Yanai K, Ido T. Appl Radiat Isot 2000; 52: 87-92.
8. Hamacher K, Hirschfelder T, Coenen, HH. Appl Radiat Isot 2002; 56: 519-523.
9. Lemaire C, Plenevaux A, Aerts J, Del Fiore G, Brihaye C, Le Bars D, Comar D, Luxen A. J Label Compd Radiopharm 1999; 42: 63-75.
10. Bauman JG, Buckman BO, Ghannam AF, Hesselgesser JE, Horuk R, Islam I, Liang M, May KB, Monahan SD, Morrissey MM, Ng HP, Shaw KJ, Wei GP, Xu W, Zhao Z, Zheng W. PCT, WO 98/56771, 17 December 1998.